Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Caris Life Sciences (CAI) stock in plain English

Free brief · no signupStart here
CAIPublished Nov 14, 2026
Caris Life Sciences Inc
Healthcare · Biotechnology
Analyzes tumor tissue and blood samples to map cancer genetics. Sells comprehensive molecular profiling tests and clinical trial matching to oncologists and drug developers.
Assets:
Irving clinical laboratoryMaintains high-throughput sequencing operations in Texas
Comprehensive molecular platformSequences tissue DNA and RNA across all 22,000 genes
Clinico-genomic repositoryHolds paired genomic and outcome records from hundreds of thousands of cases
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

61
OPS ScoreOperating finances
Latest quote
-4.92%$18.54
$5.32B
54.9×
$1.05B

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 14, 2026Quotes updated Nov 20, 04:05 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was CAI. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Caris Life Sciences (CAI) do?

Caris Life Sciences Inc (CAI) is a U.S.-listed company in Healthcare (Biotechnology). What it does: Analyzes tumor tissue and blood samples to map cancer genetics. Sells comprehensive molecular profiling tests and clinical trial matching to oncologists and drug developers. Combines whole exome and whole transcriptome sequencing with artificial intelligence to guide cancer treatment choices. It is worth $5.32B on the market and sold $1.05B over the last year.

Market cap
$5.32B
P/E ratio
54.9×
Annual sales
$1.05B
Sector
Healthcare
Industry
Biotechnology
Brief updated
Nov 14, 2026

Brands and businesses behind CAI

  • Caris Assure: A blood-based liquid biopsy assay that earns revenue by billing insurers and health systems for circulating tumor detection.
  • MI Profile: A tissue-based molecular profiling service that earns revenue from clinical diagnostic fees paid by health plans.
  • CODEai: A clinico-genomic database platform that earns revenue by licensing real-world patient records to biopharmaceutical researchers.

CAI’s flags, in plain English

Each flag is a number from Caris Life Sciences’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 14, 2026.

Stupid Cash

Can pay this year's bills 6.7 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.

Earnings Jumping

Profits up 127.8% this year. Profit per share is growing fast this year. One year does not make a trend, so check whether sales grew too.

Insiders Hold

Insiders own 55.3% of the company. The people who run the company own a meaningful slice of it, so they gain or lose along with other shareholders.

Priced for Perfection

Priced at 54.9 times its yearly profit, so a lot of growth is already expected. The share price already assumes strong results, so news that is merely good can still send it down.

1 more green flag open with the free trial. Try it free for 7 days.

Questions about CAI

How big is Caris Life Sciences?

Caris Life Sciences’ market cap is $5.32B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $1.05B: what customers paid the company over the last year, before any costs.

What is CAI’s P/E ratio?

CAI’s P/E ratio is 54.9×. Investors pay about 54.9 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.

What could go wrong with CAI?

The business relies on reimbursement decisions from Medicare and commercial health insurers that can deny or reduce coverage for broad genomic testing. That is one risk on Caris Life Sciences’ card. Its first risk flag is Priced for Perfection, explained above. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Caris Life Sciences’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. CAI’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card